DOI: 10.7759/cureus.43987

Review began 08/19/2023 Review ended 08/20/2023 Published 08/23/2023

© Copyright 2023

Yadav. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Isolated Tuberculous Mediastinal Lymphadenopathy in an Immunocompetent Child Without Pulmonary Involvement: A Case Report

Sankalp Yadav ¹

1. Medicine, Shri Madan Lal Khurana Chest Clinic, New Delhi, IND

Corresponding author: Sankalp Yadav, drsankalpyadav@gmail.com

Abstract

Tuberculosis continues to be a big challenge to public health. Isolated cases of tuberculous mediastinal lymphadenopathy in an immunocompetent child without pulmonary involvement are relatively rare. Compared to adults, children are susceptible to such infections; however, due to a lack of specific clinical features and the involvement of invasive techniques in establishing the diagnosis, there are chances of a diagnostic delay. A case of a nine-year-old girl who reported having chest pain for one month is presented. In the absence of the constitutional signs and symptoms of tuberculosis, a diagnosis was confirmed with computed tomography, histopathology, and cartridge-based nucleic acid amplification of samples obtained from endobronchial ultrasound-guided transbronchial needle aspiration. She was put on anti-tuberculous treatment for her weight.

Categories: Pediatrics, Infectious Disease, Pulmonology

Keywords: lymphadenitis, ebus tbna, mediastinal lymphadenopathy, cbnaat/xpert/rif assay, mtb (mycobacterium tuberculosis)

Introduction

Tuberculosis is a grave issue in endemic settings [1]. It is a noteworthy contributor to morbidity and mortality [2]. The data from India per the Global Tuberculosis Report 2021 states that the incidence and prevalence are 188 and 312 per one lakh (0.1 million) population, respectively [3,4]. A disease that spreads through the inhalation of infected aerosols manifests as pulmonary or extrapulmonary tuberculosis [5]. Pulmonary tuberculosis is when there are bacterial foci in the lungs; however, extrapulmonary tuberculosis (nearly 30%) is a result of the hematogenous or lymphatic spread of bacteria from the lungs to different body parts [6].

Mediastinal lymphadenopathy is a condition due to the enlargement of mediastinal lymph nodes. These enlargements could be a result of an infection like tuberculosis, metastasis, or sarcoidosis (when there is bilateral symmetrical lymph node engagement) [7]. *Mycobacterium tuberculosis* enters the lymphohematogenous system and is lodged in the mediastinal lymph nodes, resulting in swollen nodes [8]. Besides, establishing a diagnosis is challenging, as tuberculosis has been reported to mimic malignancy both radiologically and clinically [8].

A nine-year-old Indian girl presented with chest pain for one month. A detailed history, clinical examination, and serological testing were insignificant. The diagnosis was settled based on the findings of computed tomography, cartridge-based nucleic acid amplification test, and the histopathology of samples from endobronchial ultrasound-guided transbronchial needle aspiration.

Case Presentation

A nine-year-old non-diabetic Indian girl, born of a non-consanguineous marriage, with no developmental delays, was brought in by her parents with complaints of chest pain for one month. She was asymptomatic one month ago when she had pain in her chest localized to the right side. The pain was intermittent and not associated with any aggravating or relieving factors. There was no history of fever, weight loss, cough, or loss of appetite. There was no history of trauma or falls, and there was no history of tuberculosis in her or any contacts. She was fully vaccinated for her age, and there was no history of migration or stays at refugee camps or night shelters.

A general examination was suggestive of a thin-built girl with normal vital signs. Her systemic examination was insignificant in terms of any major issues. Further, there was no icterus, cyanosis, clubbing, edema, or lymphadenopathy. Her laboratory tests are shown in Table 1.

Investigation Results Reference range

HGB 10.9 15.76 o gvill. MCH 30.8 27.39 pcg MCH 30.8 gcil. 27.39 pcg MCV 20.0 31.30 gcil. MCV 41.0 38.3% to 48.6% RDW 41.0 48.3% to 48.6% RBC 4.8 47. to 6.1 million cellarinot. WBC 7.1 45.20 kVul. WBC 7.1 45.20 kVul. WBC 64 55.70% Use 20.40% 20.40% Users 20.40% 20.40% Monocytes 8 2.8% Ealinophils 1 4.4% Basophil 1 4.4% Basophil 1 4.4% Serum addium 135.0 35.15 mmolt. Serum potassium 2 3.5.1 mmolt. Serum calcium 8.10 mmolt. 3.5.1 mmolt. Serum diffuciti (folat) 3.6 3.6 mmolt. Serum diffuciti (folat) 3.5 mmolt. 3.5 mmolt. Serum diffuciti (folat)				
MCHCI 32.0 31-86 jetL MCV 92.0 65-100 ft MCV 92.0 65-100 ft PCV 41.0 33.3% to 48.8% REW 41.0 4.3% 4.7 to 6.1 million colla/mct. REC 4.8 4.7 to 6.1 million colla/mct. WBC 7.1 5-70% DLC 64 55-70% Nutrophils 64 55-70% Monocytes 3 2.28% Beninghils 1 1-4% Brain 1 1-4% Brain 1 1-4% Brain 2 2 1-1 1-1	HGB	10.9	11.5-16.0 g/dL	
MCV 92.0 85-00 f PCV 41.0 38.3% to 48.5% RDW 41.0 43.3% to 48.5% RBC 48.0 47.6 6.1 million cells/mcl. WBC 7.1 45-12.0 K/uL DLC 6 55-70% DLC 6 55-70% Lymphocytes 6 20-40% Monocytes 8 2-8% Ecsinophils 1 4-4% Basophils 1 4-4% ESR 50.0 105-22 mm/r Serum sodium 35.0 135-145 mmol/L Serum policy and collection 4-44 3-5.1 mmol/L Serum policy and collection 8.0 9.0 10-22 mm/r Serum policy and collection 9.0 15-145 mmol/L 10-145 mmol/L Serum policy and collection 9.0 9-107 mmol/L 10-145 mmol/L Serum bilirubin (indirect) 2.5 10-15 mmol/L 10-15 mmol/L Serum bilirubin (indirect) 2.5 9.0 2-10 mg/dL ALK PloS	MCH	30.6	27-33 pcg	
PCV 41.0 33.% to 48.6% RDW 13.0 0.14% RBC 4.8 4.7 to 6.1 million cells/mcl. WBC 7.1 45-12.0 K/ul. DLG	MCHC	32.0	31-36 g/dL	
RDW 13.0 0.14% RBC 4.8 4.7 to 6.1 million culluinct. WBC 7.1 4.51.2 kVul. DLC 5.70% 1.0 Neutrophile 64 5.70% Lymphocytes 20.40% 20.40% Monocytes 8 2-% Esainophils 1 1.4% Basophils 1 0.1% ESR 50.0 0.102 mm/r Serum sodium 35.0 1.35-145 mmol/L Serum calcium 8.2 3.5-1 mmol/L Serum chloride 9.0 9.0 1.0 Blood culture Serum chloride 1.0 2.10 mmol/L Serum blirubin (total) 0.20 0.2-1.0 mg/dL Serum blirubin (indirect) 0.50 0.2-1.0 mg/dL Serum blirubin (indirect) 0.5 0.2-1.0 mg/dL Alburin 3.5 3.5 g/dl Serum creatinine 0.5 0.2-1.0 mg/dL Alburin 3.0 0.40-L ALT 3.0 <	MCV	92.0	85-100 fl	
RISC 4.8 4.7 to 6.1 million cells/mcL WIGC 7.1 4.512.0 K/uL DLC 7.1 4.512.0 K/uL Neutrophils 64 55-70% Lymphocytes 26 20-40% Monocytes 8 2-8% Eosinophils 1 1-4% Basophils 1 0-1% ESR 50.0 0.22 mm/hr Serum soldium 35.0 135-145 mmol/L Serum caldium 8.2 3-5.10 mmol/L Serum caldium 8.2 3-5.10 mmol/L Serum caldium 9.0 8-107 mmol/L Serum caldium 9.0 8-107 mmol/L Serum caldium 9.0 8-107 mmol/L Serum caldium 0.6 0.2-1.0 mg/dL Serum caldium 0.6 0.2-1.0 mg/dL Serum caldium 0.2 0.2-1.0 mg/dL Serum bilirubin (total) 0.2 0.2-1.0 mg/dL Serum bilirubin (total) 0.3 0.2-1.0 mg/dL Serum bilirubin (total) 0.5	PCV	41.0	38.3% to 48.6%	
WBC 7.1 4.512.0 K/uL DLC 1 4 Neutrophils 64 55-70% Lymphocytes 26 20-40% Monocytes 8 2-8% Eosinophils 1 1-4% Basophils 1 1-7% ESR 50.0 10 c22 mm/hr Serum addium 315.0 35-145 mmol/L Serum politossium 464 35-51 mmol/L Serum caloim 90.0 8-107 mmol/L Serum chloride 99.0 8-107 mmol/L Serum chloride 1060 2-2.10 mg/dL Serum bilirubin (total) 0.60 2-2.10 mg/dL Serum bilirubin (indirect) 0.35 0.21.0 mg/dL Serum bilirubin (indirect) 0.25 0.21.0 mg/dL ALK PHOS 110.0 30-115u/L ALK PHOS 10.10 mg/dL 40-0L ALT 3.5 b g/d 40-0L ALT A.10 mg/dL 40-0L ALT 3.0 40-0L M	RDW	13.0	0-14%	
DLC Neutrophils 64 55-70% Lymphocytes 26 20-40% Monocytes 8 2-8% Ecsinophils 1 1-4% Basophils 1 0-1% ESR 50.0 0 to 22 mm/hr Serum sodium 335.0 335-145 mmol/L Serum polassium 4.64 35-51 mmol/L Serum calcium 82 35-10.5mmol/L Serum calcium 82 35-10.5mmol/L Serum chloride 99.0 38-107 mmol/L Serum chloride 500 22-10.0mg/dL Serum bilirubin (total) 306 22-1.0 mg/dL Serum bilirubin (total) 30.2 22-1.0 mg/dL Serum bilirubin (indirect) 30.2 22-1.0 mg/dL ALK PHOS 110.0 31-5.9 dig ALK PHOS 35-5.9 dig 35-5.9 dig Astructure creatinine 30 40-0u-1 AST ALT Asilah (Marcian Calcium) 40-0u-1 Active Aprila thromboplastin time 33 26-35 sec	RBC	4.8	4.7 to 6.1 million cells/mcL	
Neutrophilis 64 55-70% Lymphocytes 26 20-40% Monocytes 8 2-8% Eosinophilis 1 1-4% Basophilis 1 0-1% ESR 50.0 0 to 22 mm/hr Serum sodium 35.0 35-14 mmol/L Serum potassium 4.64 3.5-5.1 mmol/L Serum calcium 82 8.5-10.5mmol/L Serum chloride 99.0 99.107 mmol/L Blood culture Sterile Sterile Serum bilirubin (cital) 0.60 0.2-1.0 mg/dL Serum bilirubin (direct) 0.35 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 0.115u/L Albumin 3.5 3.5-5 gld Serum creatinine 0.59 0.51-0.95 mg/dL AST 4.0 4.0-u. ALT 3.0 0.40-u. Anti-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) No	WBC	7.1	4.5-12.0 K/uL	
Lymphocytes 26 20-40% Monocytes 8 2-8% Eosinophilis 1 1-4% Basophils 1 0-1% ESR 50.0 0 to 22 mm/hr Serum sodium 135.0 135-145 mmo/L Serum poliussium 4.64 3.5-5.1 mmo/L Serum calcium 8.2 8.5-10.5mmo/L Serum chloride 99.0 99-107 mmo/L Blood culture Sterile Sterile Serum bilirubin (total) 0.60 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-115u/L Albumin 3.5 3.5-5 gld Serum creatinine 0.59 0.5-10.95 mg/dL AST 29.0 0.40u/L ALT 3.3.0 0.40u/L Anti-HCV antibodies Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alph	DLC			
Monocytes 8 2-8% Eosinophils 1 1-4% Basophils 1 0-1% ESR 50.0 0 to 22 mm/hr Serum sodium 135.0 135-145 mmol/L Serum potassium 4.64 3.5-5.1 mmol/L Serum calcium 8.2 8.5-10.5mmol/L Serum chloride 99.0 98-107 mmol/L Blood culture Sterile Sterile Serum bilirubin (idirect) 0.60 0.2-1.0 mg/dL Serum bilirubin (idirect) 0.35 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 0.3115u.I Albumin 3.5 3.5-5 g/d Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0.40u/L ALT 33.0 0.40u/L ALT 3.0 0.40u/L Arti-HCV antibodies Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 7.99 mg/dL Activated partial	Neutrophils	64	55-70%	
Eosinophils 1 -4-4% Basophils 1 0-1% ESR 50.0 0 to 22 mm/hr Serum sodium 135.0 135-145 mmol/L Serum potassium 4.64 35-5-1 mmol/L Serum calcium 8.2 8.5-10.5mmol/L Serum calcium 99.0 88-107 mmol/L Serum chlinde 99.0 0-2-1.0 mg/dL Serum bilirubin (total) 0.60 0.2-1.0 mg/dL Serum bilirubin (idirect) 0.35 0.2-1.0 mg/dL Serum bilirubin (idirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-115ufL Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 3.0 0-40ufL ALT Non-reactive Reactive-Non-reactive HIV (1 and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplasti time 33 25-35 seconds Alþha-fetoproteins 30	Lymphocytes	26	20-40%	
Basophils 1 0.1% ESR 50.0 0 to 22 mm/hr Serum sodium 135.0 135-145 mmol/L Serum potassium 4.64 3.5-5.1 mmol/L Serum calcium 8.2 8.5-10.5 mmol/L Serum calcium 99.0 98-107 mmol/L Serum chloride 99.0 98-107 mmol/L Blood culture Sterile Sterile Serum bilirubin (total) 0.60 0.2-1.0 mg/dL Serum bilirubin (idirect) 0.35 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-110 sg/dL ALLY PHOS 0.59 0.51-0.95 mg/dL Serum creatinine 0.59 0.51-0.95 mg/dL AST 0.40 u.L 0.40 u.L ALT 0.01 mg/dL 0.00 mg/dL AITH-CV antibodies Non-reactive Reactive-Non-reactive Fasting blood sugar 0.00 mg/dL 0.00 mg/dL Activated partial thromboplasti time 33 2-5.5 seconds Alpha-fetoproteins	Monocytes	8	2-8%	
ESR 50.0 0 to 22 mm/hr Serum sodium 135.0 135-145 mmol/L Serum potassium 4.64 3.5-5.1 mmol/L Serum calcium 8.2 8.5-10.5mmol/L Serum chloride 99.0 98-107 mmol/L Blood culture Sterile Sterile Serum bilirubin (total) 0.60 0.2-1.0 mg/dL Serum bilirubin (direct) 0.35 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-115u/L Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0.40u/L ALT 33.0 0.40u/L ALT 3.0 0.40u/L Alt'HCV antibodies Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile <t< td=""><td>Eosinophils</td><td>1</td><td>1-4%</td></t<>	Eosinophils	1	1-4%	
Serum sodium 135.0 135.145 mmol/L Serum potassium 4.84 3.5-5.1 mmol/L Serum calcium 8.2 8.5-10.5mmol/L Serum chloride 99.0 98-107 mmol/L Blood culture Sterile Sterile Serum bilirubin (total) 0.60 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.35 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-115u/L Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0-40u/L ALT 33.0 0-40u/L Alt-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angio	Basophils	1	0-1%	
Serum potassium 4.64 3.5-5.1 mmol/L Serum calcium 8.2 8.5-10.5mmol/L Serum chloride 99.0 98-107 mmol/L Blood culture Sterile Sterile Serum bilirubin (total) 0.60 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.35 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-115u/L Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0.40u/L ALT 33.0 0.40u/L Alth-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min.	ESR	50.0	0 to 22 mm/hr	
Serum calcium 8.2 8.5-10.5mmol/L Serum chloride 99.0 98-107 mmol/L Blood culture Sterile Sterile Serum bilirubin (total) 0.60 0.2-1.0 mg/dL Serum bilirubin (idirect) 0.35 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-115u/L Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0-40u/L ALT 33.0 0-40u/L Anti-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and III) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboptastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min.	Serum sodium	135.0	135-145 mmol/L	
Serum chloride 99.0 98-107 mmol/L Blood culture Sterile Sterile Serum bilirubin (total) 0.60 0.2-1.0 mg/dL Serum bilirubin (direct) 0.35 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-115u/L Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0-40u/L ALT 33.0 0-40u/L Altr Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min.	Serum potassium	4.64	3.5-5.1 mmol/L	
Blood culture Sterile Sterile Serum bilirubin (total) 0.60 0.2-1.0 mg/dL Serum bilirubin (direct) 0.35 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-115u/L Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0-40u/L ALT 33.0 0-40u/L Anti-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min.	Serum calcium	8.2	8.5-10.5mmol/L	
Serum bilirubin (total) 0.60 0.2-1.0 mg/dL Serum bilirubin (direct) 0.35 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-115u/L Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0-40u/L ALT 33.0 0-40u/L Anti-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 40 nmol/mL/min. C-reactive proteins 0.3 0.3 to 1.0 mg/dL Bone marrow biopsy Unremarkable Unremarkable-Remarkable Echocardiography Unremarkable Unremarkable Unremarkable-Remarkable	Serum chloride	99.0	98-107 mmol/L	
Serum bilirubin (direct) 0.35 0.2-1.0 mg/dL Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-115u/L Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0-40u/L ALT 33.0 0-40u/L Anti-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min.	Blood culture	Sterile	Sterile	
Serum bilirubin (indirect) 0.25 0.2-1.0 mg/dL ALK PHOS 110.0 30-115ω/L Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0-40ω/L ALT 33.0 0-40ω/L Anti-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 μg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min.	Serum bilirubin (total)	0.60	0.2-1.0 mg/dL	
ALK PHOS 110.0 30-115u/L Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0-40u/L ALT 33.0 0-40u/L Anti-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min.	Serum bilirubin (direct)	0.35	0.2-1.0 mg/dL	
Albumin 3.5 3.5-5 g/dl Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0-40u/L ALT 33.0 0-40u/L Anti-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 μg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min.	Serum bilirubin (indirect)	0.25	0.2-1.0 mg/dL	
Serum creatinine 0.59 0.51-0.95 mg/dL AST 29.0 0-40u/L ALT 33.0 0-40u/L Anti-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min. C-reactive proteins 0.3 0.3 to 1.0 mg/dL Bone marrow biopsy Unremarkable Unremarkable-Remarkable Mantoux test 21 0-15 millimetres Echocardiography Unremarkable Unremarkable-Remarkable	ALK PHOS	110.0	30-115u/L	
AST 29.0 0-40u/L ALT 33.0 0-40u/L Anti-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min. C-reactive proteins 0.3 0.3 to 1.0 mg/dL Bone marrow biopsy Unremarkable Mantoux test 21 0-15 millimetres Echocardiography Unremarkable Unremarkable-Remarkable	Albumin	3.5	3.5-5 g/dl	
ALT 33.0 0-40u/L Anti-HCV antibodies Non-reactive Reactive-Non-reactive HIV (I and II) Non-reactive Reactive-Non-reactive Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 0.3 0.3 to 1.0 mg/dL Bone marrow biopsy Unremarkable Unremarkable-Remarkable Mantoux test 21 0-15 millimetres Echocardiography Unremarkable Unremarkable-Remarkable	Serum creatinine	0.59	0.51-0.95 mg/dL	
Anti-HCV antibodies HIV (I and II) Non-reactive Reactive-Non-reactive Reactive-Non-reac	AST	29.0	0-40u/L	
HIV (I and II) Fasting blood sugar 90.0 70-99 mg/dL Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10–20 µg/L Throat culture Sterile Serum angiotensin-converting enzyme levels 30 440 nmol/mL/min. C-reactive proteins 0.3 0.3 to 1.0 mg/dL Bone marrow biopsy Unremarkable Mantoux test Echocardiography Non-reactive Reactive-Non-reactive Reactive-Non-reactive 70-99 mg/dL 10–20 µg/L 10–2	ALT	33.0	0-40u/L	
Fasting blood sugar Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10–20 µg/L Throat culture Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min. C-reactive proteins 0.3 0.3 to 1.0 mg/dL Bone marrow biopsy Unremarkable Mantoux test Echocardiography Montoux test Unremarkable Unremarkable Unremarkable Unremarkable Unremarkable-Remarkable	Anti-HCV antibodies	Non-reactive	Reactive-Non-reactive	
Activated partial thromboplastin time 33 25-35 seconds Alpha-fetoproteins 10 10-20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min. C-reactive proteins 0.3 0.3 to 1.0 mg/dL Bone marrow biopsy Unremarkable Unremarkable-Remarkable Mantoux test 21 0-15 millimetres Echocardiography Unremarkable Unremarkable-Remarkable	HIV (I and II)	Non-reactive	Reactive-Non-reactive	
Alpha-fetoproteins 10 10–20 µg/L Throat culture Sterile Sterile Serum angiotensin-converting enzyme levels 30 <40 nmol/mL/min. C-reactive proteins 0.3 0.3 to 1.0 mg/dL Bone marrow biopsy Unremarkable Unremarkable-Remarkable Mantoux test 21 0-15 millimetres Echocardiography Unremarkable Unremarkable Unremarkable	Fasting blood sugar	90.0	70-99 mg/dL	
Throat culture Sterile Steri	Activated partial thromboplastin time	33	25-35 seconds	
Serum angiotensin-converting enzyme levels30<40 nmol/mL/min.C-reactive proteins0.30.3 to 1.0 mg/dLBone marrow biopsyUnremarkableUnremarkable-RemarkableMantoux test210-15 millimetresEchocardiographyUnremarkableUnremarkable	Alpha-fetoproteins	10	10–20 µg/L	
C-reactive proteins 0.3 0.3 to 1.0 mg/dL Bone marrow biopsy Unremarkable Unremarkable-Remarkable Mantoux test 21 0-15 millimetres Echocardiography Unremarkable Unremarkable Unremarkable	Throat culture	Sterile	Sterile	
Bone marrow biopsy Unremarkable Unremarkable Mantoux test 21 0-15 millimetres Echocardiography Unremarkable Unremarkable Unremarkable	Serum angiotensin-converting enzyme levels	30	<40 nmol/mL/min.	
Mantoux test 21 0-15 millimetres Echocardiography Unremarkable Unremarkable Unremarkable	C-reactive proteins	0.3	0.3 to 1.0 mg/dL	
Echocardiography Unremarkable Unremarkable-Remarkable	Bone marrow biopsy	Unremarkable	Unremarkable-Remarkable	
	Mantoux test	21	0-15 millimetres	
Electrocardiogram Unremarkable Unremarkable-Remarkable	Echocardiography	Unremarkable	Unremarkable-Remarkable	
	Electrocardiogram	Unremarkable	Unremarkable-Remarkable	

USG-whole abdomen Unremarkable Unremarkable Unremarkable Unremarkable

TABLE 1: Diagnostic workup of the patient

HGB: Hemoglobin; MCH: Mean Corpuscular Hemoglobin; MCHC: Mean Corpuscular Hemoglobin Concentration; MCV: Mean Corpuscular Volume; PCV: Packed cell volume; RDW: Red Cell Distribution Width; RBC: Red Blood Cell; WBC: White Blood Cell; DLC: Differential Leukocyte Count; ESR: Erythrocyte Sedimentation Rate; ALK PHOS: Alkaline Phosphatase; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; HCV: Hepatitis C Virus; USG: Ultrasonography

A chest radiograph was suggestive of right hilar lymphadenopathy with mediastinal widening (Figure 1).




FIGURE 1: Plain chest radiograph posteroanterior view

Arrow showing right hilar lymphadenopathy

She underwent an induced sputum microscopy for acid-fast bacillus and a cartridge-based nucleic acid amplification test of bronchoalveolar lavage. However, both results were negative. Her computed tomography of the chest was remarkable for multiple enlarged conglomerated necrotic lymph nodes in the mediastinum at the paratracheal, precarinal, pretracheal, subcarinal, prevascular, and right hilar regions (Figure 2 and Figure 3).



FIGURE 2: Computed tomography of the chest

Arrows showing multiple enlarged conglomerated necrotic lymph nodes in the mediastinum




FIGURE 3: Computed tomography of the chest

Arrows showing several enlarged conglomerated necrotic lymph nodes in the mediastinum

To establish the diagnosis, an endobronchial ultrasound-guided transbronchial needle aspiration was performed, as the patient's family refused a transthoracic biopsy. The samples obtained were sent for cytopathological and bacteriological examination, a cartridge-based nucleic acid amplification test/GeneXpert, a line-probe assay, and culture. The typical histological findings were suggestive of

tuberculosis (grade I pathologic result: granulomatous reaction with caseation necrosis). The cartridge-based nucleic acid amplification test/GeneXpert detected *Mycobacterium tuberculosis* (low) with no resistance to rifampicin. The results of the line-probe assay and culture were negative.

So, a final diagnosis of isolated tuberculous mediastinal lymphadenopathy in an immunocompetent child without pulmonary involvement was made, and she was initiated on anti-tubercular chemotherapy as per the national guidelines with fixed-dose combinations with details as mentioned in Table $\it 2$.

Phase	Drug	Dose	Duration
Intensive phase	Rifampicin	10 mg/kg	8 weeks
	Pyrazinamide	25 mg/kg	8 weeks
	Ethambutol	15 mg/kg	8 weeks
	Isoniazid	5 mg/kg	8 weeks
Continuation phase	Rifampicin	10 mg/kg	16 weeks
	Ethambutol	15 mg/kg	16 weeks
	Isoniazid	5 mg/kg	16 weeks

TABLE 2: Anti-tubercular chemotherapy for six months

Additionally, a tablet of pyridoxine (1 mg/kg) was also added. Currently, she has completed 20 days of her treatment and has not reported any adverse drug reactions. She was also given counseling for treatment adherence and a healthy diet with maintenance of hygiene.

Discussion

Lymphadenitis is a significant extrapulmonary manifestation of tuberculosis [9]. Tuberculous lymphadenitis contributes about 4-7% of the total tuberculosis load, with mediastinal lymphadenopathy making up about 10% of all these cases [9]. It has a proclivity for young females and children, with 20-40 years as the peak age of onset [9]. The cervical lymph nodes are the most common sites for tuberculosis; however, the mediastinal, axillary, and inguinal lymph nodes are also found to be associated with the infection [10].

The findings of mediastinal mass are a common clinical scenario in outpatient departments [7]. The diagnosis is challenging, as a number of structures lie in this anatomical area, including the lymph nodes, thymus, nerves, vessels, adipose tissue, and occasionally the thyroid gland [11]. The commonest causes of a mediastinal mass are teratoma, thyroid disease, thymoma, lymphoma, and enlarged lymph nodes due to infection, metastatic, or sarcoidosis [7]. After its entry into the respiratory system, *Mycobacterium tuberculosis* undergoes lymphohematogenous dissemination [8]. Usually, the mediastinal and hilar lymph nodes are the earliest lymphatic tissues that the bacteria will run into [8].

Diagnosis is often delayed, as the patients are mostly asymptomatic [8]. Patients become symptomatic when there is a mass effect due to enlarged lymph nodes that compress the adjacent structures, resulting in chest pain, dyspnea, or coughing [8]. A definite diagnosis is achieved after a detailed history, clinical examination, lab investigations (including tumor markers), and Gene Xpert analysis [8]. Further, the diagnosis and extent of involvement of the mediastinum can be determined by contrast computed tomography of the thorax [8]. Histopathological confirmation is essential before any therapeutic intervention [8]. Furthermore, as seen in the present case, samples for the same could be obtained by bronchoscopy or endoscopic bronchial ultrasound, allowing for fine-needle aspirate cytology or transbronchial needle aspiration [8,12]. These techniques have been found to be safe for children and can be undertaken with moderate sedation [12].

The mainstay of treatment is medical management with anti-tuberculous drugs [9]. Surgery is indicated only in extreme cases when the vital structures are compressed by the mass [9]. If not treated promptly, mediastinal lymphadenitis could end up with dysphagia due to extrinsic compression, vocal cord palsy resulting in recurrent laryngeal nerve palsy, or fistulation extending into the esophageal wall [9].

In a study by Alves et al. on 99 subjects with a mean age of 13.5 years, mediastinal lymphadenopathy was reported in 81% with a maximum diameter of 7 mm on the smallest axis [13].

A case similar to the present case was published by Kathwate in the year 2022 in an eight-year-old girl [14]. However, the present case differs from his in the absence of axillary abscess, pericardial and bilateral pleural

effusion, and ascites. Moreover, there was no aortic encasement in the present case [14].

In short, the case of a nine-year-old girl was presented here. Although mediastinal lymphadenitis is common in children, this case stresses the importance of diagnosis, especially in the absence of constitutional signs of tuberculosis. A lack of constitutional signs and symptoms could result in a diagnostic delay with unfavorable outcomes.

Conclusions

The case of a nine-year-old Indian girl with intermittent chest pain for one month is presented. A detailed history, clinical examination, and extensive laboratory workup were futile. The diagnosis was achieved based on the findings of computed tomography with a cartridge-based nucleic acid amplification test and the histopathology of samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. She was also initiated on anti-tubercular therapy. A high index of suspicion is essential for the timely diagnosis and the initiation of management in such cases.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

- Togun T, Kampmann B, Stoker NG, Lipman M: Anticipating the impact of the COVID-19 pandemic on TB
 patients and TB control programmes. Ann Clin Microbiol Antimicrob. 2020, 19:21. 10.1186/s12941-02000363-1
- Yadav S, Rawal G, Jeyaraman M: Tuberculosis of talonavicular joint without pulmonary involvement in an Indian child: a report of a rare case. Cureus. 2023, 15:e39707. 10.7759/cureus.39707
- Global tuberculosis report 2021. (2023). Accessed: August 15: https://www.who.int/publications/digital/global-tuberculosis-report-2021.
- Yadav S: Primary isoniazid mono-resistant pulmonary tuberculosis in a COVID-19-positive male: world's first case of its kind in the present pandemic. Cureus. 2022, 14:e27163. 10.7759/cureus.27163
- Jones-López EC, Acuña-Villaorduña C, Ssebidandi M, et al.: Cough aerosols of Mycobacterium tuberculosis in the prediction of incident tuberculosis disease in household contacts. Clin Infect Dis. 2016, 63:10-20. 10.1093/cid/ciw199
- Baykan AH, Sayiner HS, Aydin E, Koc M, Inan I, Erturk SM: Extrapulmonary tuberculosis: an old but resurgent problem. Insights Imaging. 2022, 13:39. 10.1186/s13244-022-01172-0
- Butler J, Barry S: Rare case of cystic anterior mediastinal tuberculosis in an immunocompetent patient. Respirol Case Rep. 2022, 10:e0987. 10.1002/rcr2.987
- 8. Maguire S, Chotirmall SH, Parihar V, et al.: Isolated anterior mediastinal tuberculosis in an immunocompetent patient. BMC Pulm Med. 2016, $16:24.\ 10.1186/s12890-016-0175-7$
- Kim J, Jang Y, Kim KO, et al.: Mediastinal tuberculous lymphadenitis diagnosed by endosonographic fine needle aspiration. Korean J Gastroenterol. 2016, 68:312-6. 10.4166/kjg.2016.68.6.312
- Ryu YJ: Diagnosis of pulmonary tuberculosis: recent advances and diagnostic algorithms. Tuberc Respir Dis (Seoul). 2015, 78:64-71. 10.4046/trd.2015.78.2.64
- Shahrzad M, Le TS, Silva M, Bankier AA, Eisenberg RL: Anterior mediastinal masses. AJR Am J Roentgenol. 2014, 203:W128-38. 10.2214/AJR.13.11998
- Fuso L, Varone F, Magnini D, Calvello M, Lo Greco E, Richeldi L: New Frontiers in ultrasonography of the mediastinum: pediatric EBUS-TBNA. Respir Care. 2019, 64:358-9. 10.4187/respcare.06831
- Alves GR, Marchiori E, Irion KL, Guimarães MD, da Cunha CF, de Souza VV, Hochhegger B: Mediastinal lymph nodes and pulmonary nodules in children: MDCT findings in a cohort of healthy subjects. AJR Am J Roentgenol. 2015, 204:35-7. 10.2214/AJR.14.12773
- $14. \quad \text{Kathwate J: Mediastinal tubercular lymph nodes completely encasing aorta in a child- a rare complication} \ . \\ \quad \text{Pediatr Oncall J. 2022, } 19:10.7199/\text{ped.oncall.2022.33}$